Le dépistage du cancer de la prostate par le PSA comporte une recommandation de grade C de l'USPSTF pour les hommes de 55 ans...
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BMA-PSA-PROSTATE-USPSTF-SHARED-DECISION |
|---|---|
| Type | Pertinence thérapeutique |
| État | reviewed 2026-05-18 | actionability review required |
| Maladies | DIS-PROSTATE |
| Sources | SRC-NCCN-GENETIC-FAMILIAL-BREAST-OVARIAN-2025 SRC-NCCN-PROSTATE-2025 SRC-USPSTF-PROSTATE-2018 |
Faits relatifs à l ' action en justice
| Biomarqueur | BIO-PSA-PROSTATE-SCREENING |
|---|---|
| Variante | PSA — Dépistage de la population / prise de décision partagée (Grade C de l'USFSTF) |
| Maladie | DIS-PROSTATE |
| Niveau ESCAT | IIIA |
| Combinaisons recommandées | Shared decision making with men 55-69 average risk (USPSTF Grade C), BRCA1/2, ATM, MMR-deficient carriers: earlier screening discussion starting age 40 (BRCA2) / 45 (BRCA1, ATM, Lynch) per NCCN Genetic 2025, Persistently rising PSA: MRI-prostate → MR-targeted + systematic biopsy rather than reflex systematic biopsy (PRECISION trial, Kasivisvanathan 2018) |
| Contre-indiqué en monothérapie | Réflexe prostatectomie sur l'APS seul pour Gleason 6 — surveillance active est la norme de soins (NCCN Prostate 2025), USPSTF grade D chez les hommes ≥70 — ne commence pas un nouveau dépistage de plus de 70 ans en dehors de la prise de décision partagée avec une espérance de vie limitée considérée |
| Résumé des faits | PSA screening for prostate cancer carries a USPSTF Grade C recommendation for men aged 55-69 — "small potential benefit" weighed against overdiagnosis / overtreatment harms — and a Grade D (recommendation against) for men ≥70 (USPSTF Prostate 2018). NCCN Prostate 2025 and AUA support shared decision making informed by family history, race (Black men: earlier / more frequent screening discussion), BRCA1/2 and Lynch carrier status (BIO-HRR-PANEL — earlier screening per NCCN Genetic/Familial 2025). Active surveillance for Gleason 6 (Grade Group 1) low-risk disease has replaced reflex prostatectomy. PSA velocity, PSA density, free/total PSA ratio, and reflex tests (4Kscore, PHI, SelectMDx) refine biopsy decisions. ESCAT IIIA — PSA directs screening / biopsy / surveillance decisions but is not a treatment-selection biomarker. |
Notes
STUB pending two-Co-Lead signoff. No standalone IND-PROSTATE-SCREENING- SHARED-DECISION entity exists yet; closest existing surveillance Indications attach to HRR-positive carriers (ind_brca_carrier_surveillance, ind_lynch_carrier_surveillance). A general-population IND-PROSTATE-SCREENING-USPSTF entity (gated on age + risk-factor profile + shared-decision-making questionnaire) is a future authoring task. Engine must NOT auto-recommend PSA screening for asymptomatic men without rendering the USPSTF tradeoff explicitly — overdiagnosis / overtreatment harms are the stated reason for Grade C (not Grade B).
Utilisé par
No reverse references found in the YAML corpus.